NCT00076869View on ClinicalTrials.gov

MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

September 30, 2004

Study Completion Date

August 31, 2005

Conditions

Aspergillosis

Interventions

DRUG

MK0991, caspofungin acetate

DRUG

Comparator: amphotericin B

DRUG

Comparator: lipid formulation of amphotericin B and/or azole

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00076869 - MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037) | Biotech Hunter | Biotech Hunter